Search
Eton Pharmaceuticals Inc
ETONAdd to Watchlist
37.500USD
+0.870+2.38%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.03BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.38%
5 Days
+10.36%
1 Month
+30.75%
6 Months
+121.76%
Year to Date
+121.76%
1 Year
+167.67%
Key Figures
36.940Open
37.975High
526.83KVolume
LossP/E TTM
20.06P/E Dynamic
--Dividend TTM
1.93%Turnover Ratio
36.630Prev. Close
36.630Low
14.93MTurnover
LossP/E Static
33.51P/B
0.00%Div Yield TTM
-1.62%ROA
35.66052wk High
1.64Volume Ratio
-3.82MNet Profit
27.36MShares
-0.0556EPS TTM
0.88Beta
-5.36%ROE
13.08552wk Low
3.67%Amplitude
60.72%Gross Margin
1.03BMarket Cap
10.47Reward/Risk
3.12%Risk Rate
TradingKey Stock Score of Eton Pharmaceuticals Inc
Currency: USD Updated: 2026-07-01Key Insights
Eton Pharmaceuticals Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 45 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 45.67.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Eton Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Eton Pharmaceuticals Inc Highlights
StrengthsRisks
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 152.67% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 79.95M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 79.95M.
Undervalued
The company’s latest PE is -659.17, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 15.99M shares, decreasing 18.71% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 15.71K shares of this stock.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
45.667
Target Price
+24.33%
Upside Space
Eton Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Eton Pharmaceuticals Inc Info
Eton Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.
Ticker SymbolETON
CompanyEton Pharmaceuticals Inc
CEOBrynjelsen (Sean E)
Websitehttps://etonpharma.com/
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
FAQs
What is the current price of Eton Pharmaceuticals Inc (ETON)?
The current price of Eton Pharmaceuticals Inc (ETON) is 36.63.
What is the symbol of Eton Pharmaceuticals Inc?
The ticker symbol of Eton Pharmaceuticals Inc is ETON.
What is the 52-week high of Eton Pharmaceuticals Inc?
The 52-week high of Eton Pharmaceuticals Inc is 35.66.
What is the 52-week low of Eton Pharmaceuticals Inc?
The 52-week low of Eton Pharmaceuticals Inc is 13.09.
What is the market capitalization of Eton Pharmaceuticals Inc?
The market capitalization of Eton Pharmaceuticals Inc is 1.00B.
Is Eton Pharmaceuticals Inc (ETON) currently rated as Buy, Hold, or Sell?
According to analysts, Eton Pharmaceuticals Inc (ETON) has an overall rating of Buy, with a price target of 45.67.
What is the Earnings Per Share (EPS TTM) of Eton Pharmaceuticals Inc (ETON)?
The Earnings Per Share (EPS TTM) of Eton Pharmaceuticals Inc (ETON) is -0.17.